Overview of Vitrakvi

Quick Facts

Property	Description
Active Ingredient	Larotrectinib (as sulfate salt)
Form	Hard Capsule, Oral Solution
Pharmacological Class	Antineoplastic Agent; Selective Kinase Inhibitor
Common Use	Treatment for NTRK gene fusion-positive solid tumors
Origin	Synthetic Organic Compound

What is Vitrakvi and its Pharmacological Class?

Vitrakvi is a prescription medicine containing the active substance Larotrectinib, a synthetic organic compound. It is categorized as an antineoplastic agent belonging to the Selective Kinase Inhibitor class, which targets specific cancer-driving mechanisms. Larotrectinib is a first-in-class oral TRK inhibitor, designed to block the Tropomyosin Receptor Kinase family of proteins. This medicine is a single-active ingredient product (monotherapy) that targets a genetic fault rather than a specific tumor site.

What are the Available Forms of Larotrectinib?

Larotrectinib is an oral medication available in two primary dosage forms: a hard capsule and an oral solution (20 mg/mL strength). The availability of both a capsule and a liquid solution allows for delivery to both adult and pediatric patients. The active substance, Larotrectinib sulfate, is combined with solid excipients for the capsule or an aqueous-based liquid vehicle for the solution. These forms are designed to be used interchangeably, providing an option for patients who may have difficulty swallowing solid medication.

What is the General Purpose of Vitrakvi?

The general purpose of Vitrakvi is to slow or halt the progression of cancer by acting on a specific molecular defect known as an NTRK gene fusion. The drug functions as a selective Tropomyosin Receptor Kinase (TRK) Inhibitor, blocking the action of the TRK fusion proteins that signal tumor cells to grow. Due to its efficacy across multiple tumor types, it is classified as a Tumor-Agnostic Therapy. By interrupting the signal for growth, the medicine promotes the inhibition of cell growth and induces cellular apoptosis (programmed cell death) in the affected tumor cells.

Regulatory References

Vitrakvi (Larotrectinib) EPAR - EMA

What side effects are possible with Vitrakvi?

The safety profile of Vitrakvi (larotrectinib) is based on clinical trial data summarized in official government regulatory documents, which categorize potential effects by frequency and body system.

Documented Adverse Reactions

The most commonly reported adverse reactions, defined as occurring in 20% or more of patients, affect multiple physiological systems. These Most Common effects include fatigue, dizziness, nausea, vomiting, constipation, diarrhea, pyrexia (fever), cough, and musculoskeletal pain. Common laboratory abnormalities reported include elevations in liver transaminases (AST increased, ALT increased) and reductions in blood cell counts (Anemia, Leukopenia).

Serious Safety Concerns

Official labeling highlights several serious safety concerns. These include the potential for Hepatotoxicity (liver injury) and Central Nervous System (CNS) Effects, which may manifest as cognitive impairment, mood disturbances, and sleep problems. Skeletal Fractures have also been documented, with a slightly higher percentage observed in pediatric patients compared to adults.

Population-Specific Notes and Safety Restrictions

Safety constraints apply to specific populations. The use of Vitrakvi is associated with a risk of Embryo-Fetal Toxicity, requiring precautions for individuals of reproductive potential. Patients diagnosed with moderate or severe hepatic impairment (Child-Pugh B or C) are required to have a 50% dose reduction at initiation, as mandated by regulatory documents. Furthermore, neurological adverse reactions are most likely to occur within the first three months of treatment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile for Vitrakvi (larotrectinib) based on the risk of exacerbating known severe toxicities, particularly affecting the Central Nervous System (CNS) and the hepatic system. High exposure may lead to the potential for severe and life-threatening outcomes, such as Grade 4 enzyme elevations or encephalopathy. Documented presentations of overexposure include severe CNS effects, such as dizziness, cognitive impairment, and confusion, as well as signs of hepatotoxicity indicated by elevated serum transaminases.

Official Overdose Statements and Actions

Management is strictly guided by mandated regulatory actions. No specific antidote for larotrectinib is documented or known. Therefore, the official guidance requires that physicians follow general supportive measures and treat the patient symptomatically. For any suspected overdose, the most critical mandated action is to seek immediate medical attention. The official labeling directs the patient to contact emergency services or a Poison Control Center if signs such as collapse, seizure, or severe difficulty breathing occur, ensuring the initiation of professional monitoring in a hospital setting. Routine prescribing information notes that patients with moderate to severe hepatic impairment require a dose reduction, indicating increased risk of overexposure in this population.

Therapeutic Uses of Vitrakvi

Quick Facts: Vitrakvi Therapeutic Scope

Condition Addressed: Solid tumors (cancer) that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.
Patient Population: Adult and pediatric patients.
Context of Use: For tumors that have spread to other areas (metastatic) or are locally advanced, where surgical removal could result in severe complications.
Treatment Position: Generally considered when satisfactory alternative options are unavailable or the condition has advanced following prior treatments.

What Vitrakvi Treats: Main Uses and Benefits

Vitrakvi (larotrectinib) is a targeted therapy indicated for the management of solid tumors in both adults and children. The use of this medication is specific to solid tumors that possess a particular genomic alteration known as a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. The tumor must not have a known acquired resistance mutation that could affect the potential benefit of the medication.

This treatment option is generally reserved for patients whose condition has become locally advanced or has spread (metastatic disease), or when surgery to remove the tumor would likely result in serious health consequences. Vitrakvi serves as a potential therapeutic approach when there are no satisfactory alternative treatments, or following a situation where the cancer has advanced despite previous systemic therapies. The prescribing physician will determine eligibility based on diagnostic testing for the NTRK gene fusion.

Regulatory References

EMA therapeutic overview

Eligibility and Restrictions for Use

Eligibility for Vitrakvi (larotrectinib) is strictly defined by the regulatory labels and depends on specific tumor characteristics and patient populations.

Eligibility Scope

Population Status	Regulatory Rule
Primary Eligibility	Must have a solid tumor with a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion.
Contraindicated	Patients with known hypersensitivity to larotrectinib or any excipients.
Not Recommended	Pregnant women and breastfeeding women.
Restricted Use	Patients with moderate or severe hepatic impairment (Child-Pugh B or C).
Age Eligibility	Approved for adult and pediatric patients; use in children less than one month of age is not established.

Condition-Based Restrictions

Official labeling mandates that use in patients with moderate to severe hepatic impairment requires a 50% reduction in the starting dose. Similarly, co-administration with a strong CYP3A4 inhibitor requires a 50% dose reduction. No specific dose adjustment is required for patients with renal impairment or mild hepatic impairment (Child-Pugh A). Both males and females of reproductive potential must use effective contraception during treatment and for at least one week following the last dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Vitrakvi (larotrectinib) has officially documented interaction patterns based on its role in drug metabolism and transport, as described in authoritative regulatory sources.

Larotrectinib is primarily metabolized by the CYP3A4 enzyme and is also a substrate for the efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). This pharmacokinetic structure dictates the potential for interaction with other products that affect these pathways. Co-administration with Strong CYP3A4 Inhibitors, such as ketoconazole, may cause a clinically significant increase in larotrectinib plasma concentrations. Conversely, co-administration with Strong CYP3A4 Inducers, like rifampicin, may cause a substantial decrease in plasma concentrations.

Larotrectinib is also a moderate inhibitor of CYP3A4. For this reason, co-administration with other medicines that are sensitive CYP3A4 substrates may lead to an increase in the plasma concentrations of the co-administered drug. The combination of Larotrectinib with the medicine Lonafarnib is formally classified as contraindicated in regulatory labeling.

Interactions with Food and Herbal Products

Consumption of Grapefruit or Grapefruit Juice and the herbal product St. John’s Wort must be avoided as they can significantly alter larotrectinib exposure via their documented effects on the metabolic system. Additionally, official labeling notes that patients with moderate to severe hepatic impairment are subject to altered disposition, requiring a specific restriction due to the heightened risk of increased drug exposure.

Mechanism of Action

Larotrectinib's mechanism is defined by its selective ability to inhibit the enzymatic activity of the abnormal TRK fusion protein. This protein, resulting from an NTRK gene fusion, possesses constitutive, unregulated tyrosine kinase activity that drives cell survival.

The drug functions as a selective kinase inhibitor, binding to the catalytic site of the TRK fusion protein (TRKA, TRKB, and TRKC) to create a direct blockade. Through this inhibition, larotrectinib suppresses the flow of growth and survival signals through critical downstream pathways, specifically the MAPK/ERK and PI3K/AKT systems. The consequence of this molecular suppression is the interruption of the cell’s pro-survival mechanisms, which initiates apoptosis (programmed cell death) and restricts further cell proliferation.

The functional integrity of this inhibition mechanism is constrained by the possibility of acquired resistance mutations within the TRK kinase domain, which can physically impede the drug's binding.

Dosage and Administration Information

How to Use Vitrakvi

Vitrakvi (larotrectinib) is administered orally in a continuous, non-cyclic schedule, maintaining treatment until the disease progresses or an unacceptable level of toxicity occurs. It is available as hard capsules (25 mg and 100 mg) and an oral solution (20 mg/mL), which are considered interchangeable for administration. The medicine may be taken with or without food.

Official Dosing Regimens and Adjustments

The standard protocol requires the medicine to be taken twice daily (BID). The dose is calculated based on the patient’s physical size, utilizing Body Surface Area (BSA) for precise determination, especially in children.

Patient Population	Standard Dosing (Twice Daily)
Adults & Pediatrics (BSA ≥ 1.0 m^2)	100 mg per dose
Pediatrics (BSA < 1.0 m^2)	100 mg/m^2 per dose (Max 100 mg)

For patients with moderate to severe hepatic impairment (liver dysfunction), the starting dose must be reduced by 50%. No initial dose adjustment is required for patients with renal impairment.

Administration Requirements

Capsules must be swallowed whole with water and must not be crushed or chewed. The oral solution may be delivered via a nasogastric feeding tube. If a patient misses a dose, the dose should be skipped if the next scheduled dose is due within 6 hours. If vomiting occurs after a dose, the patient should not take an additional dose, but should wait and take the next scheduled dose at the regular time.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Vitrakvi

Evidence for Use in NTRK Fusion-Positive Solid Tumors

Research exploring Larotrectinib (Vitrakvi) was studied for use in patients with solid tumors that have a specific genetic change, known as an NTRK gene fusion. Because this alteration is rare and was observed in many different types of cancer (such as lung, thyroid, and soft-tissue sarcoma), the key studies used a specialized single-arm trial design called a 'basket trial'. This meant the research enrolled both adult and pediatric patients with many different cancer types, provided they all shared the same NTRK fusion.

These initial studies primarily monitored outcomes related to tumor size change, specifically tracking the Objective Response Rate (ORR), which is a measurement of how many patients experienced tumor shrinkage according to standardized radiological criteria. Researchers also examined how long the tumor size remained stable or reduced, known as the Progression-Free Survival (PFS), and the Duration of Response (DOR). Studies report patterns showing that outcomes related to tumor size change were measured in the observed populations.

Since the initial trials did not compare Larotrectinib against another treatment or a placebo, regulators noted that comparative evidence is lacking. The data describe patterns that supported the evaluation of the medicine based on the genetic marker rather than the specific tumor location.

Long-Term Studies and Durability of Response

To gather more information on long-term effects, regulatory agencies often require post-market studies—non-interventional research conducted after a medicine is approved. These mandatory studies, such as the ON-TRK program, are ongoing and was evaluated in order to collect long-term data over several years. These studies research describes the length of observed response and monitors patients for several years to further evaluate long-term outcomes. Long-term effects are not fully established based on the initial approval data alone, making this ongoing research necessary.

The Current Landscape of Evidence and Key Limitations

The pivotal trial data was sourced from single-arm studies where sample sizes were modest when compared to typical randomized controlled trials for more common cancers. This non-randomized approach means comparative evidence is lacking for direct comparison against standard, non-TRK-inhibitor treatments. Furthermore, the medicine's initial approval was based on an accelerated pathway, requiring that research is ongoing to further evaluate long-term effects. The results apply only to the populations studied and reflect the specific conditions under which the research was conducted.

Frequently Asked Questions (FAQ)

Common questions about Vitrakvi (FAQ)

Q: What is the meaning of 'TRK fusion cancer'?

According to the official product information, Vitrakvi is designed to treat cancers that share a specific genetic change called an NTRK gene fusion.

This fusion results in an abnormal TRK fusion protein, which is the source of unregulated signals that are associated with cancer cells growing and surviving.

Q: Do I need to change my diet while taking Vitrakvi?

Official product information states that consumption of grapefruit or grapefruit juice and the herbal product St. John's Wort must be avoided because they can interfere with how the medicine works in the body.

Beyond these specific restrictions, the medicine may generally be taken with or without food.

Q: What are the signs that Vitrakvi is beginning to work?

Clinical studies primarily measure the signs of effectiveness by tracking changes in tumor size using imaging, which is known as the Objective Response Rate (ORR).

Researchers also monitor the time until the disease worsens, known as Progression-Free Survival. Official information primarily reports on these clinical measurements of tumor change, which are distinct from patient-perceived signs.

Q: What does 'selective tyrosine kinase inhibitor' mean in simple terms?

The medicine is classified as a selective kinase inhibitor because it is designed to selectively block only the activity of the abnormal TRK fusion protein that causes cancer.

By binding directly to this abnormal protein, it interferes with the signaling that is driving the cancer cells to grow.

Q: What should I do if I experience dizziness while taking Vitrakvi?

Dizziness is a commonly reported effect that is part of potential Central Nervous System (CNS) effects listed in regulatory documents.

It is advised that patients should avoid driving or operating hazardous machinery if they are experiencing neurotoxicity, including dizziness or cognitive impairment. Official product information suggests that any new or worsening symptoms should be discussed with a healthcare provider.

Q: Are the research results for Vitrakvi considered strong?

Official summaries indicate the medicine was approved based on data showing tumor shrinkage across many tumor types in non-comparative studies that only used a single group of patients.

The initial FDA approval was granted via an accelerated pathway, which means official documents note that ongoing research is necessary to further evaluate and confirm long-term benefit.

Q: What is the pill size/form of Vitrakvi like?

The capsule form is officially described as a white opaque hard gelatin capsule with blue printing on it.

This medicine is also available as an oral solution, providing different options for administration.

Q: What is the average duration of response reported in studies?

Clinical trial data reported a median duration of response (DOR) of approximately 32.9 months in the main group of patients studied.

This figure reflects the median length of time that tumor shrinkage was sustained in patients who showed a response during the trials.

Q: Are there any long-term side effects noted with Vitrakvi?

Serious safety concerns that have been observed include Skeletal Fractures and Hepatotoxicity (liver injury).

Furthermore, official documents note that neurological adverse reactions were primarily observed within the first three months of treatment, and long-term effects continue to be evaluated through ongoing post-market research.

Q: Can Vitrakvi affect my ability to drive or operate machinery?

Regulatory documents state that patients should avoid driving or operating hazardous machinery if they are experiencing signs of neurotoxicity.

These signs can include dizziness, cognitive impairment, or any other effect that affects focus or motor skills.

Q: How quickly do patients usually start seeing effects from Vitrakvi?

Clinical trial data noted that the median time to response—the point at which tumor shrinkage was first observed—was approximately 1.8 months.

This figure reflects the median time observed in the initial studies.

Q: Does Vitrakvi cause weight gain or weight loss?

Official clinical trial data reported that both weight gain (in 10% of patients) and weight loss (in 10% of patients) have occurred as adverse reactions.

Q: Is Vitrakvi a newer type of treatment?

According to official regulatory records, the medicine received its initial FDA approval in November 2018.

At that time, it was described as the first-ever oral TRK inhibitor and a new example of a drug approved with a tumor-agnostic indication.

Q: What kind of monitoring or blood tests are needed while on Vitrakvi?

Official documents mandate monitoring for potential liver injury. This requires liver function tests (ALT, AST, ALP, and bilirubin) to be taken before starting treatment.

Official information states that these tests are monitored every 2 weeks during the first 2 months of treatment, and then monthly thereafter, or as determined by a healthcare provider.

Q: Is Vitrakvi used for early-stage or only advanced cancer?

Regulatory indications state that the medicine is approved for solid tumors that are metastatic (cancer that has spread) or where surgical resection is likely to result in severe morbidity (serious complications).

Q: Does Vitrakvi interact with hormonal medications?

Official drug interaction information classifies Vitrakvi as a moderate inhibitor of the CYP3A4 enzyme.

Because of this, it may increase the concentrations of other medicines that are sensitive CYP3A4 substrates, a group which can include some hormonal medications.

Q: Does Vitrakvi affect fertility?

Regulatory documents caution that the medicine may affect fertility in females and may impair the ability to become pregnant.

Official information indicates that patients of reproductive potential are advised to use effective contraception during and for a period after treatment.

Q: Are there special precautions for people with high blood pressure while on Vitrakvi?

Hypertension (high blood pressure) has been reported as an adverse reaction in clinical trials.

The official information states that blood pressure should be monitored and managed as needed in patients receiving the medicine.

Q: Is Vitrakvi used as a first-line treatment or after other therapies have failed?

Regulatory indications state that the medicine is approved for solid tumors that have no satisfactory alternative treatments or that have progressed following prior treatment.

How should Vitrakvi be stored and disposed of?

Storage and Disposal Requirements for Vitrakvi (Larotrectinib)

Official regulatory documents define specific storage requirements based on the medicine's form.

Formulation	Required Storage Condition	Key Restriction
Hard Capsules	Controlled room temperature (20 C to 25 C)	None
Oral Solution	Refrigerator (2 C to 8 C)	Do not freeze

Both the capsules and the oral solution must be stored in their original container and kept out of the sight and reach of children.

For the Oral Solution, any unused portion must be discarded after 90 days (100 mL bottle) or 31 days (50 mL bottle) from the first opening, regardless of how much remains. Do not use the medicine after the expiration date.

Disposal: Unused or expired Vitrakvi must not be thrown away in household trash or wastewater. Consult a pharmacist for instructions on proper disposal according to local regulations.

Vitrakvi